Perspective Therapeutics, Inc. annual report, FY2014

Business context and reporting period

The supplied filing is IsoRay, Inc.’s Form 10-K for the fiscal year ended June 30, 2014—not a 2013 Q4 filing. The filing identifies the registrant as IsoRay, Inc., not Perspective Therapeutics, Inc.; confirm the company and period before relying on this summary. IsoRay developed, manufactured and sold Cesium-131 brachytherapy products, principally Proxcelan seeds, and the GliaSite brain-radiation system.

Financial performance and liquidity

Sales declined 7%. Gross margin moved from positive $150,176 to a $196,471 loss. Cost of product sales rose about 1% despite lower sales, with the medical-device excise tax and GliaSite costs among the increases. Operating expenses were $4.392 million, up 4%. The net loss also reflected a $1.382 million noncash loss from revaluing warrant derivative liabilities, versus a $210,000 gain in FY2013.

At June 30, 2014, cash and cash equivalents were $7.680 million, short-term investments $10.003 million, and other investments $5.401 million; total assets were $26.549 million and total liabilities $2.593 million. The balance sheet reports no conventional borrowings. At September 19, 2014, the company reported total cash and investments of approximately $22.068 million. Management estimated monthly cash operating expenditures of about $269,000 in FY2014. Operating cash burn increased 6% year over year.

Material changes versus the prior comparable period

• Prostate product sales fell 5% to $3.526 million; they represented 84% of revenue, up from 82% because non-prostate revenue declined faster.
• Other product sales fell 13% to $693,289. GliaSite revenue increased approximately 33% (about $57,000), while non-prostate treatment results were mixed: gynecological and head-and-neck revenue rose, but brain and lung revenue declined.
• FY2014 financing generated $23.450 million net cash, including a March 2014 registered direct offering with $13.815 million net proceeds and proceeds from warrant and option exercises. Common shares outstanding rose from 34.6 million at June 30, 2013 to 54.7 million at June 30, 2014.
• Cash and investments rose substantially after capital raising, while the company continued to incur operating losses and negative operating cash flow.

Outlook, commentary, risks and contingencies

Management planned to expand Proxcelan use, build GliaSite distribution and pursue non-prostate indications, supported by clinical studies and sales efforts. It estimated break-even at about $750,000 monthly revenue and operating cash-flow break-even at about $700,000 monthly, but gave no assurance it would achieve those levels. Management expected FY2015 protocol expenses of no more than $250,000 and capital equipment spending of no more than $100,000, and said available funds should cover at least 12 months and, at the current expense rate, at least five years.

• Commercial and concentration risks: The business relied mainly on one product and prostate procedures; five customers accounted for approximately 49.74% of FY2014 sales, with one accounting for about 26.75%. Management cited market decline, screening trends, active surveillance, competition from IMRT and robotic surgery, and differences in reimbursement incentives.
• Supply risk: About 80% of FY2014 Cesium-131 came from a Russian supplier. A contract extension ran through March 31, 2015; domestic production at the Missouri University Research Reactor was being developed as a mitigating source. Management estimated its enriched barium inventory could last 24–36 months. Russian supply, payment, political and single-reactor risks remain.
• Reimbursement and tax: CMS reimbursement policies could change, and inpatient hospitals pay for some products from bundled DRG payments. The company stated the 2.3% medical-device tax applied to its product sales and could materially affect results and cash flows.
• Other risks and contingencies: Regulatory approvals, slow adoption, product liability, radioactive-material handling, short product half-life, sole-source components and foreign-market execution could adversely affect operations. The filing discloses a disputed know-how royalty matter that could proceed to arbitration, and potential recapture of $515,853 in prior QTDP grant funds if costs fail IRS review. No material legal proceedings were reported; the auditor issued an unqualified opinion.

Important facts for investors to verify

• Confirm the registrant and reporting period: the supplied document is IsoRay’s FY2014 10-K, not a Perspective Therapeutics filing or 2013 Q4 report.
• Reconcile the company’s reported September 2014 liquidity, financing proceeds and subsequent cash use with the full statements and later filings.
• Check the status, terms and renewal of the Russian isotope supply agreement and the scale, cost and reliability of domestic Cesium-131 production.
• Track revenue trends, gross margins, product mix, customer concentration and whether non-prostate products achieve broader adoption.
• Assess potential dilution from outstanding options, warrants and preferred-stock rights, as well as the company’s ability to fund continuing operating losses without further financing.